Andrew Catchpole

1.3k citations

21 papers · 329 indexed · h-index 10

Impact in

Infectious Diseases top 10%
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
Modeling and Simulation top 10%
- COVID-19 epidemiological studies

Papers in ⓘ

Epidemiology 13
- Respiratory viral infections research 12
- Influenza Virus Research Studies 6
- Pneumonia and Respiratory Infections 2
Infectious Diseases 8
- Viral gastroenteritis research and epidemiology 4
- SARS-CoV-2 and COVID-19 Research 3

Co-authors: Rob Lambkin‐Williams (8 shared papers)Anthony Gilbert (5 shared papers)Alex Mann (5 shared papers)Nicolas Noulin (6 shared papers)John Oxford (3 shared papers)Christopher Chiu (4 shared papers)Shobana Balasingam (2 shared papers)Alex Mann (7 shared papers)
Journals: PLoS ONE (3 papers)Antiviral chemistry & chemotherapy (2 papers)New England Journal of Medicine (2 papers)Respiratory Research (1 paper)EClinicalMedicine (1 paper)
Partner nations: United Kingdom United States Netherlands

In The Last Decade

Andrew Catchpole

20 papers receiving 303 citations

Peers

Countries citing papers authored by Andrew Catchpole

Since Specialization

Citations

This map shows the geographic impact of Andrew Catchpole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Catchpole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Catchpole more than expected).

Fields of papers citing papers by Andrew Catchpole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Catchpole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Catchpole. The network helps show where Andrew Catchpole may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Catchpole, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Catchpole Line = papers co-authored together Andrew Catchpole links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study New England Journal of Medicine ·Beate Schmöele-Thoma, Agnieszka Zareba, Qin Jiang, Mohan S. Maddur, Rana Danaf, Alex Mann, Kingsley Eze, Juin Fok‐Seang, Golam Kabir, Andrew Catchpole, Daniel A. Scott, Alejandra Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Kena A. Swanson	2022	79
2	The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics Respiratory Research ·Rob Lambkin‐Williams, Nicolas Noulin, Alex Mann, Andrew Catchpole, Anthony Gilbert	2018	43
3	Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study The Lancet Microbe ·Jie Zhou, Anika Singanayagam, Niluka Goonawardane, Maya Moshe, Fiachra Sweeney, Ksenia Sukhova, Ben Killingley, Mariya Kalinova, Alex Mann, Andrew Catchpole, Michael R. Barer, Neil M. Ferguson, Christopher Chiu, William Barclay	2023	35
4	SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic New England Journal of Medicine ·Garth Rapeport, Emma Smith, Anthony Gilbert, Andrew Catchpole, Helen McShane, Christopher Chiu	2021	31
5	Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge PLoS ONE ·Alex Mann, Nicolas Noulin, Andrew Catchpole, Koert J. Stittelaar, Leon de Waal, Edwin J. B. Veldhuis Kroeze, Michael Hinchcliffe, Alan Smith, Emanuele Montomoli, Simona Piccirella, Albert D. M. E. Osterhaus, Alastair D. Knight, John Oxford, Giulia Lapini, Rebecca Jane Cox, Rob Lambkin‐Williams	2014	27
6	A Throat Lozenge Containing Amyl Meta Cresol and Dichlorobenzyl Alcohol Has a Direct Virucidal Effect on Respiratory Syncytial Virus, Influenza a and SARS-CoV Antiviral chemistry & chemotherapy ·John Oxford, Rob Lambkin‐Williams, Iain Gibb, Shobana Balasingam, Charlotte Chan, Andrew Catchpole	2005	27
7	Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults Biomedicine & Pharmacotherapy ·Jia Yao Phuah, Brian M. Maas, Aimin Tang, Ying Zhang, Luzelena Caro, Radha Railkar, Michael D. Swanson, Yu Cao, Hankun Li, Brad Roadcap, Andrew Catchpole, Antonios O. Aliprantis, Kalpit A. Vora	2023	22
8	Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene Journal of General Virology ·Andrew Catchpole, Louise J. Mingay, Ervin Fodor, G.G. Brownlee	2003	14
9	Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model PLoS ONE ·Daniel J. Fullen, Nicolas Noulin, Andrew Catchpole, Hosnieh Fathi, Edward J. Murray, Alex Mann, Kingsley Eze, Ganesh Balaratnam, Daryl W. Borley, Anthony Gilbert, Rob Lambkin‐Williams	2016	9
10	Changes in memory and cognition during the SARS-CoV-2 human challenge study EClinicalMedicine ·William Trender, Peter J. Hellyer, Ben Killingley, Mariya Kalinova, Alex Mann, Andrew Catchpole, David Menon, Edward Needham, Ryan S. Thwaites, Christopher Chiu, Gregory Scott, Adam Hampshire	2024	9
11	New Antiviral Drugs, Vaccines and Classic Public Health Interventions against SARS Coronavirus Antiviral chemistry & chemotherapy ·John Oxford, Shobana Balasingam, Charlotte Chan, Andrew Catchpole, Rob Lambkin‐Williams	2005	9
12	Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM) Journal of Virological Methods ·Geraldine Kelly, Carl Laxton, Mariam Garelnabi, Brian Alton, Fatima Addan, Andrew Catchpole, E. Donnall Thomas, Daryl W. Borley, Kieran Dee, Alison Boyers, Erica Bringas, Nicolas Noulin, Rob Lambkin‐Williams, Edward J. Murray	2015	6
13	The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process BMC Research Notes ·Andrew Catchpole, Daniel J. Fullen, Nicolas Noulin, Alex Mann, Anthony Gilbert, Rob Lambkin‐Williams	2018	6
14	A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model PLoS ONE ·Daniel J. Fullen, Bryan Murray, Julie Mori, Andrew Catchpole, Daryl W. Borley, Edward J. Murray, Ganesh Balaratnam, Anthony Gilbert, Alex Mann, Fiona Hughes, Rob Lambkin‐Williams	2016	5
15	Viral Emissions into the Air and Environment after SARS-CoV-2 Human Challenge: A Phase 1, Open Label, First-in-Human Study SSRN Electronic Journal ·Jie Zhou, Anika Singanayagam, Niluka Goonawardane, Maya Moshe, Fiachra Sweeney, Ksenia Sukhova, Ben Killingley, Mariya Kalinova, Alex Mann, Andrew Catchpole, Michael R. Barer, Neil M. Ferguson, Christopher Chiu, William Barclay	2022	2
16	Human Challenge Trial of a Nucleoside-Modified Messenger Ribonucleic Acid Influenza Vaccine NEJM Evidence ·Kelly Lindert, Alex Mann, Anita Geevarughese, Teresa Hauguel, Sarah Mirza, Melissa Bevan, Kevin Yi, K.S. Wolfe, Pascale V. Nantermet, Kingsley Eze, Pratiksha Dokhe, Agnieszka Zareba, Emily Gomme, Andrew Catchpole, Annaliesa S. Anderson, Alejandra Gurtman, Pirada Suphaphiphat Allen	2025	1
17	The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic Epidemics ·Maria Piggin, Emma Smith, Peter Mankone, Leah Ndegwa, Diane Gbesemete, Philippa Pristerà, Michael Bahrami‐Hessari, Halle Johnson, Andrew Catchpole, Peter Openshaw, Christopher Chiu, Robert C. Read, Helen Ward, Caroline Barker	2022	1
18	A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus Pulmonary Therapy ·Mickie Cheng, Alex Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea Schaeffer, Lin Liao, Andrew Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S De Anda	2025	1
19	Torsional Vibrations of a Vehicle Drive Line Journal of Mechanical Design ·Andrew Catchpole, S. P. Healy, D. Hodgetts	1978	1
20	Late Breaking Abstract - Experimental Respiratory Syncytial Virus infection in adults 60-75 years Alex Mann, Mariya Kalinova, Andrew Catchpole, Olesya Rusyn, Veronika Horváthová, Kingsley Eze, M. L. Rodríguez de, Alan Bell	2020	1

About Andrew Catchpole

Andrew Catchpole is a scholar working on Epidemiology, Infectious Diseases, Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Organic Chemistry, having authored 21 papers that have together received 329 indexed citations. Recurring topics across this work include Respiratory viral infections research (12 papers), Influenza Virus Research Studies (6 papers), Viral gastroenteritis research and epidemiology (4 papers), Viral Infections and Immunology Research (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Pneumonia and Respiratory Infections (2 papers), Infection Control and Ventilation (1 paper) and Long-Term Effects of COVID-19 (1 paper). The work is most often cited by research in Infectious Diseases (141 citations), Modeling and Simulation (26 citations), Epidemiology (180 citations), Pulmonary and Respiratory Medicine (76 citations) and Health (19 citations). Andrew Catchpole has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Rob Lambkin‐Williams, Anthony Gilbert, Alex Mann, Nicolas Noulin, John Oxford, Christopher Chiu, Shobana Balasingam, Alex Mann, Agnieszka Zareba and Kena A. Swanson. Their work appears in journals such as PLoS ONE, Antiviral chemistry & chemotherapy, New England Journal of Medicine, Respiratory Research and EClinicalMedicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact